

We Claim:

1. An isolated polynucleotide comprising a nucleotide sequence which hybridizes under stringent conditions to a sequence selected from the group consisting of SEQ ID NOS: 1-6010.

2. An isolated polynucleotide comprising at least 15 contiguous nucleotides of a nucleotide sequence having at least 90% sequence identity to a sequence selected from the group consisting of: SEQ ID NOS:1-6010, a degenerate variant of SEQ ID NOS:1-6010, an antisense of SEQ ID NOS:1-6010, and a complement of SEQ ID NOS:1-6010.

3. An isolated polynucleotide comprising at least 15 contiguous nucleotides of a nucleotide sequence selected from the group consisting of: SEQ ID NOS:1-6010, a degenerate variant of SEQ ID NOS:1-6010, an antisense of SEQ ID NOS:1-6010, and a complement of SEQ ID NOS:1-6010.

4. The isolated polynucleotide of claim 3, wherein the polynucleotide comprises at least 100 contiguous nucleotides of the nucleotide sequence.

5. The isolated polynucleotide of claim 3, wherein the polynucleotide comprises at least 200 contiguous nucleotides of the selected nucleotide sequence.

6. An isolated polynucleotide comprising a nucleotide sequence of at least 90% sequence identity to a sequence selected from the group consisting of: SEQ ID NOS:1-6010, a degenerate variant of SEQ ID NOS:1-6010, an antisense of SEQ ID NOS:1-6010, and a complement of SEQ ID NOS:1-6010.

7. The isolated polynucleotide of claim 6, wherein the polynucleotide comprises a nucleotide sequence of at least 95% sequence identity to the selected nucleotide sequence.

8. The isolated polynucleotide of claim 6, wherein the polynucleotide comprises a nucleotide sequence that is identical to the selected nucleotide sequence.

9. A polynucleotide comprising a nucleotide sequence of an insert contained in a clone deposited as ATCC Accession No. PTA-2027, PTA-2028, PTA-2029, PTA-2030, PTA-2031, PTA-2032, PTA-2033, PTA-2034, PTA-2035, PTA-2036, PTA-2037, PTA-2038, PTA-2039, PTA-2040, PTA-2041, PTA-2042, PTA-2043, PTA-2044, PTA-2045, PTA-2046, PTA-2047, PTA-2050, PTA-2051, PTA-2052, PTA-2053, PTA-2054, PTA-2055, PTA-2056, PTA-2057, PTA-2058, PTA-

2059, PTA-2060, PTA-2061, PTA-2062, PTA-2048, PTA-2049, PTA-2063, PTA-2064, PTA-2065, PTA-2066, PTA-2067, or PTA-2068.

10. An isolated cDNA obtained by the process of amplification using a polynucleotide  
5 comprising at least 15 contiguous nucleotides of a nucleotide sequence of a sequence selected from the group consisting of SEQ ID NOS:1-6010.

11. The isolated cDNA of claim 10, wherein the polynucleotide comprises at least 25  
10 contiguous nucleotides of the selected nucleotide sequence.

12. The isolated cDNA of claim 10, wherein the polynucleotide comprises at least 100  
contiguous nucleotides of the selected nucleotide sequence.

13. The isolated cDNA of claims 10, 11, or 12, wherein amplification is by polymerase  
15 chain reaction (PCR) amplification.

14. An isolated recombinant host cell containing the polynucleotide according to claims 1,  
2, 3, 6, 9, or 10.

15. An isolated vector comprising the polynucleotide according to claims claims 1, 2, 3, 6,  
20 9, or 10.

16. A method for producing a polypeptide, the method comprising the steps of:  
culturing a recombinant host cell containing the polynucleotide according to claims claims  
25 1, 2, 3, 6, 9, or 10., said culturing being under conditions suitable for the expression of an encoded polypeptide;  
recovering the polypeptide from the host cell culture.

17. An isolated polypeptide encoded by the polynucleotide according to claims claims 1, 2,  
30 3, 6, 9, or 10.

18. An antibody that specifically binds the polypeptide of claim 17.

19. A method of detecting differentially expressed genes correlated with a cancerous state of a mammalian cell, the method comprising the step of:

detecting at least one differentially expressed gene product in a test sample derived from a cell suspected of being cancerous, where the gene product is encoded by a gene comprising an identifying sequence of at least one of SEQ ID NOS:1-6010;

wherein detection of the differentially expressed gene product is correlated with a cancerous state of the cell from which the test sample was derived.

20. A library of polynucleotides, wherein at least one of the polynucleotides comprises the sequence information of the polynucleotide according to claims 1, 2, 3, 6, 9, or 10.

21. The library of claim 20, wherein the library is provided on a nucleic acid array.

22. The library of claim 20, wherein the library is provided in a computer-readable format.

23. A method of inhibiting tumor growth by modulating expression of a gene product, the gene product being encoded by a gene identified by a sequence selected from the group consisting of SEQ ID NOS:1-6010.